We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High BIM mRNA levels are associated with longer survival in advanced gastric cancer.
- Authors
NANDIE WU; YING HUANG; ZHENGYUN ZOU; GIMENEZ-CAPITAN, ANA; LIXIA YU; WENJING HU; LIJING ZHU; XIA SUN; SANCHEZ, JOSE JAVIER; WENXIAN GUAN; BAORUI LIU; ROSELL, RAFAEL; JIA WEI
- Abstract
Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS). All 131 patients received first-line FOLFOX combination chemotherapy with folinic acid and 5-FU, in which 56 patients were further treated with second-line docetaxel-based chemotherapy. A correlation between the mRNA expression levels of BIM and AEG-1 was observed (rs=0.30; P=0.002). There was no association between the mRNA expression levels of any of the individual genes analyzed and OS in patients only receiving first-line FOLFOX chemotherapy. In a subgroup of patients receiving docetaxel-based second-line chemotherapy, those with high or intermediate levels of BIM exhibited a median OS of 18.2 months [95% confidence interval (CI), 12.8-23.6], compared with 9.6 months (95% CI, 8.9-10.3) in patients with low BIM levels (P=0.008). However, there was no correlation between the mRNA expression levels of AEG-1 or AXL and OS. The risk of mortality was higher in patients with low BIM mRNA levels than in those with high or intermediate BIM mRNA levels (hazard ratio, 2.61; 95% CI, 1.21-5.62; P=0.010). Therefore, BIM may be considered as a biomarker to identify whether patients could benefit from docetaxel-based second-line chemotherapy in GC.
- Subjects
BCL-2 proteins; MESSENGER RNA; STOMACH cancer treatment; CANCER chemotherapy; FLUOROURACIL; DRUG resistance
- Publication
Oncology Letters, 2017, Vol 13, Issue 3, p1826
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2017.5660